Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission

New drug combinations have led to significant improvements in remission rates for patients with acute myeloid leukemia (AML). However, many patients with high‐risk AML who respond to their initial treatment and are not candidates for allogeneic stem cell transplantation (ASCT) will eventually relapse with poor outcomes.

[1]  Complete Remission , 2020, Definitions.

[2]  H. Döhner,et al.  The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission , 2019 .

[3]  T. Kadia,et al.  Maintenance therapy in AML: The past, the present and the future , 2019, American journal of hematology.

[4]  E. Vellenga,et al.  Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. , 2019, Blood.

[5]  M. Coleman,et al.  Adult leukemia survival trends in the United States by subtype: A population‐based registry study of 370,994 patients diagnosed during 1995‐2009 , 2018, Cancer.

[6]  F. Ravandi,et al.  Evaluating measurable residual disease in acute myeloid leukemia. , 2018, Blood advances.

[7]  Sin-Ho Jung,et al.  Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Bernard,et al.  Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial , 2017, Blood Cancer Journal.

[9]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[10]  Asim Khwaja,et al.  Acute myeloid leukaemia , 2016, Nature Reviews Disease Primers.

[11]  Yashma Patel,et al.  Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.

[12]  D. Blaise,et al.  Hematopoietic stem cell transplantation for patients with AML in first complete remission. , 2016, Blood.

[13]  Christopher A. Miller,et al.  Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. , 2015, JAMA.

[14]  A. Wei,et al.  Maintenance lenalidomide in combination with 5‐azacitidine as post‐remission therapy for acute myeloid leukaemia , 2015, British journal of haematology.

[15]  R. Hills,et al.  A Comparison of Limited Consolidation Chemotherapy Therapy Or Not, and Demethylation Maintenance Or Not in Older Patients with Aml and High Risk Mds: Long Term Results of the Uk Ncri Aml16 Trial , 2015 .

[16]  I. Lewis,et al.  Maintenance Lenalidomide for Adults Aged 18-65 Years with AML in First Complete Remission after Intensive Chemotherapy: A Phase Ib Dose-Escalation Study of the Australasian Leukemia and Lymphoma Group (ALLG) , 2014 .

[17]  M. Boccadoro,et al.  Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents , 2014, Annals of Hematology.

[18]  R. Hills,et al.  Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Issa,et al.  A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission , 2012, Leukemia.

[20]  Z. Berneman,et al.  Natural killer cell immune escape in acute myeloid leukemia , 2012, Leukemia.

[21]  A. Verma,et al.  Mechanism of action of lenalidomide in hematological malignancies , 2009, Journal of hematology & oncology.

[22]  Hisashi Sakamaki,et al.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.

[23]  P. Dickman,et al.  Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. , 2009, Blood.

[24]  S. Fröhling,et al.  Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. , 2006, Blood.

[25]  S. Jagannath,et al.  Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.

[26]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[27]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[28]  D. Grimwade,et al.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.